OptiNose Expands Senior Management Team with Three Key Appointments in Core Business Areas of Operations, Regulatory Affairs an

 OptiNose Expands Senior Management Team with Three Key Appointments in Core
    Business Areas of Operations, Regulatory Affairs and Commercialization

PR Newswire

YARDLEY, Pa., June 12, 2014

YARDLEY, Pa., June 12, 2014 /PRNewswire/ -- OptiNose, a global specialty
pharmaceuticals company, today announced three appointments to the Company's
senior management team. This expansion of the executive leadership will help
drive the Company forward in its mission to introduce new and valuable
treatment options to the market utilizing its novel Bi-Directional™ Breath
Powered™ Delivery Technology. The recently appointed executives have served at
some of the most prestigious companies in the health care and life sciences
industry, and together they bring more than 65 years of industry experience to
OptiNose.

Ramona Lloyd, Ph.D. has joined the Company as Vice President, Regulatory
Affairs & Quality. Dr. Lloyd has held executive leadership positions in
Regulatory Affairs and Quality with such companies as Sanofi-Aventis, Bristol
Myers-Squibb, and Johnson & Johnson. Following her time as Vice President,
Regulatory Affairs with Bristol-Myers Squibb, she acted as Senior Vice
President of Regulatory Affairs and Safety for ImClone Systems, a wholly-owned
subsidiary of Eli Lilly and Company. Most recently she has served as a
consultant in regulatory affairs to the pharmaceutical industry.

Sheila Bergey has joined the Company as Vice President, Operations & Program
Management. Mrs. Bergey spent 25 years with Johnson & Johnson where she held
leadership positions in Operations, Supply Chain, Change Management –
including Strategic Planning, Program Management, Information Technology,
Process Excellence and Procurement. Interested in the challenges of more
entrepreneurial ventures, she founded Saybrook Consulting LLC and then was
appointed Chief Operating Officer of Lindi Skin, a skin care company in the
Philadelphia area. Most recently, Mrs. Bergey was with MannKind Corporation, a
bio-pharmaceutical company focused on developing drug-device combination
product technologies.

Terrence Terifay has joined the Company as Senior Vice President and Chief
Commercial Officer. Most recently, Mr. Terifay held commercial leadership
positions at Mallinckrodt, including Vice President, Marketing and interim
General Manager, Branded Specialty Pharmaceuticals. Prior to Mallinckrodt, he
was the Executive Vice President, Chief Operating Officer, Synchrony
Healthcare Group. He has also held positions of leadership and roles with
increasing responsibility at Cephalon, Purdue Pharma and Johnson & Johnson.

"I am excited to welcome Ramona, Sheila and Terry to OptiNose and to our
senior management team," said Peter Miller, Chief Executive Officer of
OptiNose. "Their combined years of experience and significant strengths in
their respective fields will help solidify our position as a specialty
pharmaceuticals company and help advance our core pipeline. I am excited to
have them on board and believe their collective skills and experience will be
highly complementary to the talented group of colleagues already in the
company."

About OptiNose
OptiNose is a Specialty Pharmaceutical Company built around a unique nasal
delivery platform. The bi-directional™ Breath Powered™ device platform
provides dramatically enhanced delivery of drug into the nasal cavity versus
current treatments. When used to deliver select medications, the technology
can enable value enhanced products with important new efficacy or safety
characteristics. OptiNose has created single and multi-use devices for
intranasal delivery of both liquid and powder drug formulations. The strongly
patent-protected technology has been successfully tested in a number of
clinical trials evaluating the advantages of this new technology. OptiNose is
developing a pipeline of assets currently for the treatment of Central Nervous
System disorders and Nasal Inflammatory Diseases. For more information, please
visit www.optinose.com.

Investors in OptiNose include Avista Capital Partners in New York, WFD
Ventures LLC located in New York and Entrepreneurs Fund LP based in Jersey,
Channel Islands.



SOURCE OptiNose

Website: http://www.optinose.com
Contact: OptiNose Media Contact: Hilary Mra, hilary.mra@hkstrategies.com,
212-885-0550
 
Press spacebar to pause and continue. Press esc to stop.